Publication Name	World Journal of Gastroenterology
Manuscript ID	6965
Country	United States

Received	2013-10-31 09:22
Peer-Review Started	2013-10-31 19:30
To Make the First Decision	2014-01-09 16:51
Return for Revision	2014-01-12 17:43
Revised	2014-01-15 04:07
Second Decision	2014-02-20 09:09
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-02-20 09:24
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-03-25 11:49
Publish the Manuscript Online	2014-04-04 15:11

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Therapeutic drug monitoring in patients with inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Andres J Yarur, Maria T Abreu, Amar R Deshpande, David H Kerman and Daniel A Sussman
Funding Agency and Grant Number
Corresponding Author	Daniel A Sussman, MD, Division of Gastroenterology, University of Miami Leonard Miller School of Medicine, 1120 NW 14th Street, Suite 310F3 (D-49), Miami, FL 33136, United States. dsussman@med.miami.edu
Key Words	Inflammatory bowel disease; Anti-tumor necrosis factor; Infliximab; Adalimumab; Drug level; Azathioprine; Thiopurines; Antibodies; Drug monitoring; Thioguanine
Core Tip	The use of thiopurine analogs and anti-tumor necrosis factor (TNF) agents in patients with inflammatory bowel diseases (IBD) has improved outcomes. The pharmacokinetics of thiopurines is variable among patients, and some do not benefit from these drugs. The manipulation and monitoring of thiopurines can potentially increase response to treatment and/or reduce the development of toxicity. The efficacy of anti-TNF drugs is also variable and several factors can modify drug clearance, including the concomitant use of immunomodulators, systemic inflammation, the presence of anti-drug antibodies, and body mass. The treatment of IBD has advanced with the understanding of the pharmacologic profiles of immunomodulating and TNF-inhibiting medications.
Publish Date	2014-04-04 15:11
Citation	Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3475-3484
URL	http://www.wjgnet.com/1007-9327/full/v20/i13/3475.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i13.3475

Full Article (PDF)	WJG-20-3475.pdf
Full Article (Word)	WJG-20-3475.doc
Manuscript File	6965-Review.docx
Answering Reviewers	6965-Answering reviewers.pdf
Copyright License Agreement	6965-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	Ethics_Committee_20131030070315.docx
Peer-review Report	6965-Peer review(s).pdf
Scientific Editor Work List	6965-Scientific editor work list.doc